CDR-404

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameCDR-404
Drug Alias NameCDR-404CDR404
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Melanoma-associated antigen 4
TargetsMelanoma-associated antigen 4
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCDR-Life Inc
China Registration ClassN/A

Develop Information

Active CompaniesCDR-Life IncCDR-Life AG
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A